Sana narrows focus to ex vivo cell therapies, lays off 29% of staff to reach key clinical data
Sana Biotechnology will let go about 29% of its staff, or roughly 120 employees, to focus on its ex vivo cell therapies, according to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
